Related Experiment Videos
[Concomitant intraperitoneal therapy with the antitumor polysaccharide Sizofiran and rG-CSF for ovarian cancer]
T Hoshino1, Y Suzuki, M Takeichi
1Dept. of Obstetrics and Gynecology, Tokyo Medical College.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 1, 1993
Abstract:
The concomitant administration of Sizofiran (a macrophage activator) and rG-CSF (which promotes neutrophil proliferation and activation) caused marked activation of intraperitoneal antitumor immunity. It promoted the induction of IL-2 receptor expression as well as the proliferation and activation of neutrophils, and also caused an increase in LAK and NK activity, which resulted in a clinical antitumor effect. Therefore, this concomitant regimen was found to be useful as maintenance therapy for ovarian cancer.